MUNICH, Germany, Sept. 29 /PRNewswire/ -- Nomad Bioscience GmbH announces that it entered into a broad licensing agreement with Bayer Innovation GmbH and Icon Genetics group. It provides Nomad access to Icon's proprietary technology platforms, including its transient expression technology magnICON(R), for manufacturing biomaterials and selected biosimilar pharmaceutical proteins in green plants. The agreement provides Nomad with a strategically needed freedom to operate in its core business areas. The financial terms of the agreement are not disclosed.
"Icon Genetics' proprietary gene transfer systems provide a broad solution to the upstream part of manufacturing, and combined with Nomad downstream technologies, they should result in a superior fully integrated process for most of our intended product candidates," said Dr. Yuri Gleba, the founder of Nomad Bioscience. Prof. Dr. Gleba is also co-inventor of Icon's technologies as well as co-founder and managing director of Icon Genetics.
"Icon has developed new generation production platforms that are by far more effective than those commercialized today. Since our own strategic focus is on proprietary biopharmaceuticals, we were looking for a partner who could best apply our proprietary expression methods to other new classes of products," said Dr. Detlef Wollweber, Managing Director of Bayer Innovation.
About Nomad Bioscience:
Nomad Bioscience, headquartered in Munich, is a private start-up biotechnology company developing a series of high value materials such as nanopatterned materials, protein scaffolds, proteins and enzymes for important markets including biosimilar biopharmaceuticals, electric batteries and biofuels.
CONTACT: Prof. Dr. Yuri Gleba of Nomad Bioscience GmbH, +49-345-555-9887,